Cyclacel Pharmaceuticals

$7.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.07 (+0.95%) Today
+$0.07 (+0.94%) As of 1:34 PM UTC after-hours

Why Robinhood?

You can buy or sell CYCC and other stocks, options, and ETFs commission-free!

About CYCC

Cyclacel Pharmaceuticals, Inc. Common Stock, also called Cyclacel Pharmaceuticals, is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ. The listed name for CYCC is Cyclacel Pharmaceuticals, Inc. Common Stock.

CEO
Spiro Rombotis
Employees
12
Headquarters
Berkeley Heights, New Jersey
Founded
1996
Market Cap
38.94M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
364.63K
High Today
$7.52
Low Today
$7.23
Open Price
$7.38
Volume
144.99K
52 Week High
$19.25
52 Week Low
$3.12

Collections

CYCC Earnings

-$2.90
-$1.93
-$0.97
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 24, After Hours

You May Also Like

SSY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure